Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5-6/2006

01-11-2006 | Original Paper

Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells

Authors: Meghan E. Minard, Lee M. Ellis, Gary E. Gallick

Published in: Clinical & Experimental Metastasis | Issue 5-6/2006

Login to get access

Abstract

The guanine nucleotide exchange factor Tiam1 regulates numerous biologic properties including migration and invasion. We demonstrated previously that colon tumor cells biologically selected for increased migration were increased in Tiam1 expression. Cells selected for increased Tiam1 expression or that ectopically overexpress Tiam1 were increased in metastatic potential. Here, we demonstrate that Tiam1 regulates additional functions associated with metastasis, including reduced cellular adhesion and resistance to anoikis. Tiam1 effects on cellular migration are mediated through its downstream substrate, Rac. Increased Tiam1 expression also leads to anoikis-resistance, whereas decreasing Tiam1 expression by siRNA sensitizes cells to this form of apoptosis; however, Tiam1’s regulation of anoikis is Rac-independent. Staurosporine sensitivity is also Rac-independent, suggesting Tiam1’s effects on apoptosis require other effectors. As many of the observed phenotypes are characteristic of a transition of transformed epithelial cells to a mesenchymal-like phenotype, we also examined biochemical properties associated with an EMT. We demonstrate an increase in vimentin expression in cell lines that overexpress Tiam1 and have a more metastatic phenotype. Concomitant with this increase, we observe a decrease in E-cadherin expression in these cells. Lastly, we stained a panel of human colorectal specimens and adjacent normal tissue, and demonstrate that Tiam1 is overexpressed in a subset of human colorectal tumors. In summary, in colon tumor cells, Tiam1 affects multiple properties associated with acquisition of the metastatic phenotype, and may represent a marker of colon tumor progression and metastasis in a subset of tumors.
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef
2.
Zaniboni A, Labianca R (2004) Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol 15:1310–1318PubMedCrossRef
3.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
4.
Minard ME, Herynk MH, Collard JG, Gallick GE (2005) The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. Oncogene 24:2568–2573PubMedCrossRef
5.
Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG (1995) A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 375:338–340PubMedCrossRef
6.
Haeusler LC, Blumenstein L, Stege P, Dvorsky R, Ahmadian MR (2003) Comparative functional analysis of the Rac GTPases. FEBS Lett 555:556–560PubMedCrossRef
7.
Habets GG, Scholtes EH, Zuydgeest D, van der Kammen RA, Stam JC, Berns A, Collard JG (1994) Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell 77:537–549PubMedCrossRef
8.
Rogers S, Wells R, Rechsteiner M (1986) Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234:364–368PubMedCrossRef
9.
Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, Collard JG, Der CJ (2002) Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 4:621–625PubMed
10.
van Leeuwen FN, van der Kammen RA, Habets GG, Collard JG (1995) Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. Oncogene 11:2215–2221PubMed
11.
Stam JC, Sander EE, Michiels F, van Leeuwen FN, Kain HE, van der Kammen RA, Collard JG (1997) Targeting of Tiam1 to the plasma membrane requires the cooperative function of the N-terminal pleckstrin homology domain and an adjacent protein interaction domain. J Biol Chem 272:28447–28454PubMedCrossRef
12.
Michiels F, Stam JC, Hordijk PL, van der Kammen RA, Ruuls-Van Stalle L, Feltkamp CA, Collard JG (1997) Regulated membrane localization of Tiam1, mediated by the NH2-terminal pleckstrin homology domain, is required for Rac-dependent membrane ruffling and C-Jun NH2-terminal kinase activation. J Cell Biol 137:387–398PubMedCrossRef
13.
Habets GG, van der Kammen RA, Stam JC, Michiels F, Collard JG (1995) Sequence of the human invasion-inducing TIAM1 gene, its conservation in evolution and its expression in tumor cell lines of different tissue origin. Oncogene 10:1371–1376PubMed
14.
Engers R, Zwaka TP, Gohr L, Weber A, Gerharz CD, Gabbert HE (2000) Tiam1 mutations in human renal-cell carcinomas. Int J Cancer 88:369–376PubMedCrossRef
15.
Hou M, Tan L, Wang X, Zhu YS (2004) Antisense Tiam1 down-regulates the invasiveness of 95D cells in vitro. Acta Biochim Biophys Sin (Shanghai) 36:537–540CrossRef
16.
Malliri A, van der Kammen RA, Clark K, Van Der Valk M, Michiels F, Collard JG (2002) Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417:867–871PubMedCrossRef
17.
Otsuki Y, Tanaka M, Yoshii S, Kawazoe N, Nakaya K, Sugimura H (2001) Tumor metastasis suppressor nm23H1 regulates Rac1 GTPase by interaction with Tiam1. Proc Natl Acad Sci U S A 98:4385–4390PubMedCrossRef
18.
Adam L, Vadlamudi RK, McCrea P, Kumar R (2001) Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta -catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 276:28443–28450PubMedCrossRef
19.
Minard ME, Kim LS, Price JE, Gallick GE (2004) The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 84:21–32PubMedCrossRef
20.
Liu L, Wu DH, Ding YQ (2005) Tiam1 gene expression and its significance in colorectal carcinoma. World J Gastroenterol 11:705–707PubMed
21.
Leibovitz A, Stinson JC, McCombs WB III, McCoy CE, Mazur KC, Mabry ND (1976) Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36:4562–4569PubMed
22.
Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE (2002) Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21:7797–7807PubMedCrossRef
23.
Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD, Gallick GE (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273:1052–1057PubMedCrossRef
24.
Savagner P (2001) Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23:912–923PubMedCrossRef
25.
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRef
26.
Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746PubMedCrossRef
27.
Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W (2004) Essential role of BCL9–2 in the switch between beta-catenin’s adhesive and transcriptional functions. Genes Dev 18:2225–2230PubMedCrossRef
28.
Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L (2001) IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20:4942–4950PubMedCrossRef
29.
Yeh CS, Wang JY, Wu CH, Chong IW, Chung FY, Wang YH, Yu YP, Lin SR (2006) Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol 28:411–420PubMed
30.
Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85–88PubMedCrossRef
31.
Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48:6863–6871PubMed
32.
Malliri A, Rygiel TP, van der Kammen RA, Song JY, Engers R, Hurlstone AF, Clevers H, Collard JG (2005) The RAC activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumour development. J Biol Chem, epub Oct 05, Printed 2006, 281: 543–548
33.
Yeh CS, Wang JY, Wu CH, Chong IW, Chung FY, Wang YH, Yu YP, Lin SR (2006) Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol 28:411–420
34.
Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA, Collard JG (2000) Rho family proteins in cell adhesion and cell migration. Eur J Cancer 36:1269–1274PubMedCrossRef
35.
Robson EJ, Khaled WT, Abell K, Watson CJ (2006) Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation 74:254–264PubMedCrossRef
36.
Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365–370PubMedCrossRef
37.
Engers R, Springer E, Michiels F, Collard JG, Gabbert HE (2001) Rac affects invasion of human renal cell carcinomas by upregulating TIMP-1 and TIMP-2 expression. J Biol Chem 276:41889–41897PubMedCrossRef
38.
Hordijk PL, ten Klooster JP, van der Kammen RA, Michiels F, Oomen LC, Collard JG (1997) Inhibition of invasion of epithelial cells by Tiam1-Rac signaling. Science 278:1464–1466PubMedCrossRef
39.
Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG (1999) Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 147:1009–1022PubMedCrossRef
40.
Uhlenbrock K, Eberth A, Herbrand U, Daryab N, Stege P, Meier F, Friedl P, Collard JG, Ahmadian MR (2004) The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. J Cell Sci 117:4863–4871PubMedCrossRef
41.
Bourguignon LY, Zhu H, Shao L, Chen YW (2000) CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem 275:1829–1838PubMedCrossRef
42.
Bourguignon LY, Zhu H, Shao L, Chen YW (2000) Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J Cell Biol 150:177–191PubMedCrossRef
43.
Ehler E, van Leeuwen F, Collard JG, Salinas PC (1997) Expression of Tiam-1 in the developing brain suggests a role for the Tiam-1-Rac signaling pathway in cell migration and neurite outgrowth. Mol Cell Neurosci 9:1–12PubMedCrossRef
44.
Fleming IN, Gray A, Downes CP (2000) Regulation of the Rac1-specific exchange factor Tiam1 involves both phosphoinositide 3-kinase-dependent and -independent components. Biochem J 351:173–182PubMedCrossRef
45.
van Leeuwen FN, Kain HE, Kammen RA, Michiels F, Kranenburg OW, Collard JG (1997) The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho. J Cell Biol 139:797–807PubMedCrossRef
46.
Supriatno, Harada K, Kawaguchi S, Yoshida H, Sato M (2003) Effect of p27Kip1 on the ability of invasion and metastasis of an oral cancer cell line. Oncol Rep 10:527–532PubMed
47.
Hamelers IH, Olivo C, Mertens AE, Pegtel DM, van der Kammen RA, Sonnenberg A, Collard JG (2005) The Rac activator Tiam1 is required for (alpha)3(beta)1-mediated laminin-5 deposition, cell spreading, and cell migration. J Cell Biol 171:871–881PubMedCrossRef
48.
Servitja JM, Marinissen MJ, Sodhi A, Bustelo XR, Gutkind JS (2003) Rac1 function is required for Src-induced transformation: evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J Biol Chem 278:34339–34346PubMedCrossRef
49.
Strumane K, Rygiel TP, Collard JG (2005) The rac activator tiam1 and ras-induced oncogenesis. Methods Enzymol 407:269–281PubMed
Metadata
Title
Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells
Authors
Meghan E. Minard
Lee M. Ellis
Gary E. Gallick
Publication date
01-11-2006
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 5-6/2006
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-006-9040-z

Other articles of this Issue 5-6/2006

Clinical & Experimental Metastasis 5-6/2006 Go to the issue

Original Paper

Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents

Original Research

Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase

Original Paper

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model

Original Paper

Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-β pathway

Original paper

Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA

ORIGINAL PAPER

Neutrophil activator of matrix metalloproteinase-2 (NAM)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits